PTPRC and B-cell non-Hodgkin lymphoma: The modification allows anti-CD45 CAR T cells to avoid recognizing and targeting these edited cells while efficiently targeting blood cancer cells expressing normal CD45, including patient-derived acute myeloid leukemia, B-cell lymphoma, and acute T-cell leukemia.